D. E. Shaw & Co., Inc. Sarepta Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 4,478,638 shares of SRPT stock, worth $100 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
4,478,638
Previous 4,406
101548.62%
Holding current value
$100 Million
Previous $281,000
27154.09%
% of portfolio
0.06%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding SRPT
# of Institutions
462Shares Held
83.3MCall Options Held
5.6MPut Options Held
4.19M-
Black Rock Inc. New York, NY10.3MShares$231 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.16MShares$205 Million0.0% of portfolio
-
State Street Corp Boston, MA4.7MShares$105 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA2.53MShares$56.6 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.24MShares$50.2 Million0.01% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.96B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...